SCHEMBL2900405

SCHEMBL2900405

O=C1c2c(O)c(=O)n(CC3COCCO3)c(=O)n2CCN1Cc1ccc(F)cc1

nearest known ligand 0.40

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
FEN1 P39748 1/20 0.40
KCNH2 Q12809 2/20 0.39
GRM2 Q14416 1/20 0.39
AKR1B1 P15121 1/20 0.36
CYP2D6 P10635 1/20 0.35
HRH3 Q9Y5N1 1/20 0.35
TP53 P04637 2/20 0.35
RAB9A P51151 1/20 0.34
ALDH1A1 P00352 1/20 0.34
POLB P06746 1/20 0.34
DRD4 P21917 1/20 0.34
GRIN2B Q13224 1/20 0.34
CLPP Q16740 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2893714 0.84 ALDH1A1 (0.37) KCNH2GRM2AKR1B1TP53RAB9A
SCHEMBL2897900 0.82 KCNH2 (0.36) KCNH2GRM2AKR1B1ALDH1A1DRD4
SCHEMBL2895163 0.82 TP53 (0.38) KCNH2GRM2AKR1B1CYP2D6HRH3
SCHEMBL2897685 0.79 TP53 (0.34) KCNH2GRM2AKR1B1CYP2D6HRH3
SCHEMBL2898803 0.78 KCNH2 (0.38) KCNH2GRM2AKR1B1CYP2D6HRH3
SCHEMBL2891898 0.77 KCNH2 (0.42) KCNH2GRM2AKR1B1CYP2D6HRH3
SCHEMBL2900483 0.77 MEN1 (0.37) KCNH2GRM2AKR1B1CYP2D6TP53
SCHEMBL2900613 0.76 KCNH2 (0.39) KCNH2GRM2AKR1B1CYP2D6HRH3
SCHEMBL2900361 0.76 GAA (0.37) KCNH2GRM2AKR1B1CYP2D6TP53
SCHEMBL2898869 0.76 KCNH2 (0.37) KCNH2GRM2AKR1B1CYP2D6HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7820680-B2 HIV integrase inhibitors MERCK & CO., INC. (US) 2010-10-26 US claimed
EP-1725102-A4 HIV INTEGRASE INHIBITORS MERCK & CO INC (US) 2009-04-29 EP claimed
US-20080009490-A1 Hiv Integrase Inhibitors MERCK SHARP & DOHME CORP. 2008-01-10 US claimed
EP-1725102-A1 HIV INTEGRASE INHIBITORS Merck & Co., Inc. (US) 2006-11-29 EP claimed
WO-2005092099-A1 HIV INTEGRASE INHIBITORS MERCK & CO., INC. (US) 2005-10-06 WO claimed
US-7820680-B2 HIV integrase inhibitors MERCK & CO., INC. (US) 2010-10-26 US disclosed
US-7820680-B2 HIV integrase inhibitors MERCK & CO., INC. (US) 2010-10-26 US disclosed
US-20080009490-A1 Hiv Integrase Inhibitors MERCK SHARP & DOHME CORP. 2008-01-10 US disclosed
US-20080009490-A1 Hiv Integrase Inhibitors MERCK SHARP & DOHME CORP. 2008-01-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080009490-A1 Hiv Integrase Inhibitors TYMS, UNG, TYMP FEN1 53/4885KCNH2 3441/4885GRM2 4668/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.